Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Dose Radiotherapy and Chemotherapy in Medulloblastoma
NCT00031590Phase 2Terminated
- Sponsor
- Children's Hospital of Philadelphia
- Start
- Apr 2001
- Primary completion
- May 2011
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Cisplatin micelle injection (HA132), cyclophosphamide, etoposide, lomustine and vincristine sulfate liposome injection in medulloblastoma, sponsored by Children's Hospital of Philadelphia. Primary endpoint: Rate of Late Neurotoxic Effects at 3 years. Started Apr 2001; status: terminated.
02
Drugs
Cisplatin micelle injection (HA132)cyclophosphamideetoposidelomustinevincristine sulfate liposome injection
03
Conditions
medulloblastoma
Beyond the preview
Go deeper on NCT00031590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00031590.